mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overactive Bladder (OAB)
Conditions
Overactive Bladder (OAB)
Trial Timeline
Jul 20, 2018 → Sep 13, 2019
NCT ID
NCT03602508About mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine is a pre-clinical stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT03602508. Target conditions include Overactive Bladder (OAB).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03602508 | Pre-clinical | Completed |
Competing Products
20 competing products in Overactive Bladder (OAB)